Seneca biopharma, inc. (CUR)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net loss

-8,351

-4,924

-15,665

-21,074

-20,903

-22,628

-19,831

-10,121

-12,518

-18,387

-10,364

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization

143

185

289

337

345

348

244

211

187

130

88

Share-based compensation expense

880

634

1,769

3,445

2,951

4,320

2,331

1,610

3,333

5,240

4,556

Amortization of deferred financing fees and debt discount

-

-

59

347

870

-

-

-

-

-

-

Amortization of deferred financing fees and debt discount

-

-

-

-

-

829

694

0

0

-

-

Warrant modification expense

-

-

-

-

-

3,109

5,017

0

0

-

-

Gain from change in fair value of warrant obligations

-

-

-

-

0

334

965

0

-161

-

-

(Gain) loss on fair value of liability classified warrants

499

3,269

-1,470

660

-

-

-

-

-

-

-

Provision for bad debt

362

-

-

-

-

-

-

-

-

-

-

Warrant inducement expense

-

-

563

0

-

-

-

-

-

-

-

Expenses related to issuance of liability classified warrants

-

-

242

466

0

-

-

-

-

-

-

Loss on disposal of fixed assets and patent abandonment

-

-18

-8

-10

0

-

-

-

-

-

-

Loss on debt extinguishment

-

-

-

-

-

-445

0

0

-

-

-

Changes in operating assets and liabilities:
Warrant issuance and modification expense

-

-

-

-

-

-

-

-

-

1,906

-

Gain from change in fair value of derivative instruments

-

-

-

-

-

-

-

-

-

-1,352

83

Trade and other receivables

-272

-18

302

-26

-188

215

6

-231

234

-

-

Related party receivable

-

-62

-53

477

0

-

-

-

-

-

-

Prepaid expenses

142

-32

-297

-513

840

-191

-125

-164

27

43

7

ROU and other assets

-39

3

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-322

327

2

Other assets

-

-

-1

-55

13

-6

5

-15

14

-

-

Accounts payable and accrued expenses

-15

-36

-1,522

879

-1,045

-

-

-

888

213

243

Accrued bonuses

135

-418

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

1,382

-116

-644

-

-

-

Accrued bonuses

-

-

-434

691

-485

181

0

24

129

-67

423

Other current liabilities

-47

11

-230

-21

253

-2

2

30

0

-

-

Lease and other long term liabilities

-34

-1

-

-

-

-

-

-

-

-

-

Other long term liabilities

-

-

-16

-155

-250

-9

-11

0

0

-

-

Net cash used in operating activities

-7,255

-7,692

-13,416

-15,616

-

-

-

-

-

-9,981

-5,144

Cash flows from investing activities:
Purchases of short-term investments

-

-

5,000

5,000

7,517

25,007

0

0

-

-

-

Net cash used in operating activities

-

-

-

-

-18,931

-11,706

-10,591

-8,477

-8,096

-

-

Maturity of short-term investments

-

5,000

5,000

7,517

15,007

10,000

0

0

-

-

-

Patent costs

-

-

82

63

67

348

411

215

284

256

122

Purchase of property and equipment

-

1

11

98

176

207

125

39

196

76

88

Net cash provided by investing activities

-

4,998

-94

2,356

-

-

-

-

-

-332

-210

Cash flows from financing activities:
Net cash (used in) provided by investing activities

-

-

-

-

7,246

-15,563

-537

-254

-480

-

-

Proceeds from issuance of common stock from warrants exercised, net of issuance costs

-

-

3,225

0

3,073

-

-

-

-

-

-

Net proceeds from the sale of common stock and warrants

6,552

1,828

5,510

28,118

2,931

-

-

-

-

-

-

Proceeds from warrant exercises

0

-

-

-

-

-

-

-

-

-

-

Payments of taxes on stock option exercises

-

-

-

-

802

426

0

0

-

-

-

Proceeds from long-term debt transactions, net of issuance costs

-

-

-

-

-

4,212

7,551

0

0

-

-

Payments of long-term debt

-

-

3,765

4,569

1,154

1,929

0

0

-

-

-

Proceeds from issuance of common stock from warrants exercised, net

-

-

-

-

-

1,794

6,107

204

1,668

7,993

-

Proceeds from sale of common stock and warrants, net of issuance costs

-

-

-

-

-

19,467

7,048

13,685

0

9,271

2,762

Payment on fees for future financing

-

-

-

-

45

0

0

-

-

-

-

Proceeds from short term notes payable

414

349

346

313

0

-

-

-

-

-

-

Payments of short-term note payable

377

363

326

124

117

175

183

65

-

-

-

Net cash provided by (used in) financing activities

6,589

1,814

4,990

23,738

-

-

-

-

-

17,265

2,762

Payments on Note Payable

-

-

-

-

-

-

-

-

0

-

-

Net cash (used in ) provided by financing activities

-

-

-

-

3,887

22,944

20,524

13,824

1,668

-

-

Effects of exchange rates on cash

-6

-7

-0

-0

-4

-0

6

0

-

-

-

Effects of exchange rates on cash

-

-

-

-

-

-

-

-

0

-

-

Net increase (decrease) in cash and cash equivalents

-672

-887

-8,520

10,478

-7,802

-4,327

9,402

5,091

-6,909

6,951

-2,593

Supplemental disclosure of cash flows information:
Cash paid for interest

-

-

-

-

954

762

624

2

0

2

0

Cash paid for income taxes

-

-

-

0

0

0

0

0

-

0

0

Cash paid for income taxes

-

-

-

-

-

-

-

-

0

-

-

Cash paid for interest

8

7

118

990

-

-

-

-

-

-

-

Extinguishment of warrant obligations through exercise, expiration and modification

-

-

-

-

-

-

-

-

-

-6,563

-

Issuance of common stock for cashless exercise of options, warrants and RSUs

-

-

-

8

1,981

-

-

-

-

-

-

Issuance of common stock for cashless exercise of warrants and options

-

-

-

-

-

1,208

587

0

-

-

-

Issuance of common stock for conversion of long-term debt

-

-

-

-

-

1,000

0

0

-

-

-

Issuance of common stock for cashless exercise of warrants

-

-

-

-

-

-

-

-

0

-

-

Issuance of common stock for fees related to debt issuance

-

-

-

-

-

-

-

-

0

-

-

Issuance of warrants for fees related to debt issuance

-

-

-

-

-

-

-

-

0

-

-

Extinguishment of warrant obligations through exercise, expiration and modification

-

-

-

-

-

-

-

-

1,089

-

-

Issuance of common stock for services, net of returned shares for amended agreement

-

-

-

-

-

-

-

-

565

-

-

Issuance of common stock and options for executive bonuses

-

-

-

-

-

-

-

-

77

-

-

Financing of insurance premiums through note payable

-

-

-

-

-

210

183

146

0

-

-

Issuance of common stock and warrants for fees related to debt transactions

-

-

-

-

-

159

848

0

-

-

-

Issuance of common stock for exercise of restricted stock units

-

-

-

-

-

-

-

-

0

-

-

Issuance of warrants for vendor services

-

-

-

-

-

0

658

0

0

-

-

Issuance of common stock for services, net of returned shares for amended agreement

-

-

-

-

-

-

-

175

-

-

-

Issuance of common stock from executive bonuses

-

-

-

-

-

-

-

-

-

-248

-372